✦ LIBER ✦

Immunotherapy for metastatic renal cell carcinoma

✍ Scribed by David F. McDermott; Brian I. Rini

Book ID: 109053190
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 137 KB
Volume: 99
Category: Article
ISSN: 1464-4096
DOI: 10.1111/j.1464-410x.2007.06818.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Immunotherapy for metastatic renal-cell

Immunotherapy for metastatic renal-cell carcinoma

✍ A. Belldegrun; R. Figlin; G. Haas; J. deKernion 📂 Article 📅 1991 🏛 Springer-Verlag 🌐 English ⚖ 385 KB

Sarcomatoid differentiation as a prognos

Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma

✍ Cheol Kwak; Yong Hyun Park; Chang Wook Jeong; Hyeon Jeong; Sang Eun Lee; Kyung C 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB

High-dose interleukin-2 immunotherapy is

High-dose interleukin-2 immunotherapy is safe for patients with metastatic renal cell carcinoma on dialysis

✍ JOHN P. BRUSKY; FAWEZ GAILANI; APURBA PATHAK; HATEL PATEL; SHERIF ABOSEIF 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

Combined cytoreductive laser therapy and

Combined cytoreductive laser therapy and immunotherapy for palliation of metastatic renal cell carcinoma to the head and neck

✍ M. B. Paiva; J. A. Sercarz; A. J. Pantuck; M. Polyakov; R. A. Figlin; R. F. Cana 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 112 KB

Treatment selection for patients with me

Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy

✍ Michael B. Atkins 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 192 KB

Granulocyte-macrophage–colony stimulatin

Granulocyte-macrophage–colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma : Results of two Phase II clinical trials

✍ Christopher W. Ryan; Nicholas J. Vogelzang; Mary C. Dumas; Timothy Kuzel; Walter 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 2 views

The aim of this study was to determine the response rates and toxicity of two regimens containing granulocyte-macrophage-colony stimulating factor (GM-CSF) in combination with interleukin-2 (IL-2) in the treatment of patients with metastatic renal cell carcinoma. ## METHODS. Therapy given in the f